SAVIMS

Ivermectin

COVID-19, Covid-19 vaccines, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

Comprehensive Overview of the I-RECOVER Post-Vaccine Treatment Protocol

Reference: Kory, P., & Marik, P. (2024). I-RECOVER: Post-vaccine treatment protocol. Summary: The I-RECOVER Post-Vaccine Treatment Protocol offers a detailed approach for managing symptoms associated with COVID-19 vaccination injuries. It categorises therapies into first, second, and third-line options, focusing on restoring immune regulation and addressing various clinical manifestations. Key first-line therapies include intermittent fasting, ivermectin, […]

COVID-19, Ivermectin, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Practical Ivermectin Guidelines Powerpoint Presentation

References: Powerpoint Presentation of Practical Guidelines for the therapeutic use of Ivermectin citing various publications. Compiled 2023, Dr Stephen J Schmidt. Summary: A powerpoint presentation highlighting the history of Avermectins and consequent development of the therapeutic drug commonly known as Ivermectin. The uses for various medical conditions are listed, as well as suggested protocol for

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Overview of Early COVID-19 Treatment Protocols

Reference: FLCCC Alliance. (2023). I-CARE early COVID treatment summary. Retrieved from https://www.flccc.net Summary: The FLCCC Alliance outlines a structured protocol for the early treatment of COVID-19, emphasising the importance of immediate intervention after the onset of symptoms. First-line treatments include Ivermectin (0.4-0.6 mg/kg), Hydroxychloroquine (200 mg twice daily), and antiseptic mouthwash for symptom management. Ivermectin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

I-CARE Early COVID Treatment Protocol Overview

Reference: FLCCC Alliance. (2023). I-CARE: Early COVID treatment protocol. Retrieved from [insert link] Summary: The I-CARE protocol, developed by the FLCCC Alliance, aims to provide healthcare professionals with a structured approach to early COVID-19 treatment, focusing on preventing hospitalisation and mortality. The protocol recommends a combination of first-line treatments such as ivermectin, hydroxychloroquine, and various

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Prevention Strategies Against COVID-19, Influenza, and RSV – SUMMARY

Reference: FLCCC Alliance. (2023). I-PREVENT COVID, FLU AND RSV protection. Retrieved from www.flccc.net Summary: The I-PREVENT protocol is designed for healthcare workers, high-risk individuals, and those with co-morbidities to mitigate the risks of COVID-19, influenza, and RSV infections. Recommended interventions include antiseptic mouthwashes containing chlorhexidine, povidone-iodine, or cetylpyridinium chloride, and supplementation with Vitamin D, Vitamin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Preventative Protocols for COVID-19, Influenza, and RSV

Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic

COVID-19, Covid-19 vaccines, Ivermectin, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

Hemagglutination Induced by SARS-CoV-2 Spike Protein: Clinical Implications

Reference: Boschi, C., Scheim, D. E., Bancod, A., Millitello, M., Le Bideau, M., Colson, P., Fantini, J., & La Scola, B. (2022). SARS-CoV-2 spike protein induces hemagglutination: Implications for COVID-19 morbidities and therapeutics and for vaccine adverse effects. bioRxiv. https://doi.org/10.1101/2022.11.24.517882 Summary: The study investigates the hemagglutination (HA) induced by SARS-CoV-2 spike proteins from various lineages

Scroll to Top